Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Trial ID or NCT#
Status
Purpose
The overall objective of this drug trial is to determine whether the treatment of acute hyperammonemia with N-carbamyl-L-glutamate (NCG, Carglumic acid) in propionic acidemia (PA), methylmalonic acidemia (MMA), late-onset CPS1 deficiency (CPSD) and late-onset Ornithine transcarbamylase deficiency (OTCD) accelerates the resolution of hyperammonemia efficiently and safely. The primary goal is to determine if the study drug (NCG) efficiently reduces ammonia levels following a hyperammonemia episode(s). Secondly, the investigators want to know if treatment with this study drug (NCG) efficiently improves neurologic function, reduces plasma glutamine levels and lessens the duration of hospitalization after each episode of hyperammonemia.
Official Title
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jennafer Dotson
650-724-1881
View on ClinicalTrials.gov